
|Articles|August 1, 2006
- Pharmaceutical Executive-08-01-2006
- Volume 0
- Issue 0
How Far We've Come
In 1981, pharma was a more innocent industry. It stood on the brink of an AIDS epidemic that science had yet to name or understand. Hazards of generics, product lifecycles, and off-label marketing lay years ahead. There were no embryonic stem cells to fight over--nor euphemisms like "overactive bladder syndrome" and "erectile dysfunction" to ease conversations or kick off ad campaigns. Who knew what awaited us? To remember--and to reflect on what shaped modern pharma--we invite you to page through the most significant events of the past quarter century.
Advertisement
Articles in this issue
about 20 years ago
Time Machineabout 20 years ago
Getting Betterabout 20 years ago
States Curb Marketingabout 20 years ago
From the Editor: Take Your Seatabout 20 years ago
Viewpoint: In Your Wordsabout 20 years ago
Quiz Answersabout 20 years ago
Introduction: Pharm Exec at 25Advertisement
Related to this article

The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.

Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.

As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.

TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.

The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy.

Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.

Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
2
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
3
The Most Important Lessons Learned from Building CGT Supply Chains: LogiPharma 2026
4
Viatris Acquires Pacira BioSciences for $1.65 Billion
5

